NCHR testifies against drug Romosozumab for having cardiac safety issues.
Read More »We’re Speaking Out on Health Issues
NCHR scientists and health policy experts provide written and oral statements on a wide range of topics.
Here are many of the ways we have been Speaking Out on Health Policy Issues for the last few years. Whether the topic is legislation intended to cure diseases, proposed bans on BPA or other chemicals that disrupt your hormones, the importance of including women, people of color, and patients over 65 in clinical trials, or many other topics, you’ll gain a better understanding of our evidence-based analyses by reading these letters, statements, and testimony.
Here are the ways we have been Speaking out on Medical Treatments and Products, such as prescription drugs and medical devices that the FDA is considering approving, or is considering taking off the market because of serious risks. Whether the topic is Chantix, Addyi, Yaz, Essure, or medical products you’ve never heard of, you can find out more about what is known and not known about the safety and effectiveness of a wide range of products by looking through this section of our website.
Here are our Statements and Positions on issues that affect you.
Testimony at FDA on Sotagliflozin to Help Manage Type 1 Diabetes
January 17, 2019. Just providing new treatment options is not enough. New treatments must provide a real tangible benefit for patients without too much risk.
Read More »NCHR Comments on Prescription Drug-Use-Related Software
January 10, 2019. Digital Health is a new area of healthcare covering a broad set of technologies with diverse applications in healthcare. The proposed risk-based framework provides an important foundation for prescription drug-use-related software, but several important issues remain.
Read More »NCHR Testimony at FDA at the Circulatory System Devices Panel Meeting
NCHR testified at the FDA circulatory system device panel meeting to urge the committee to hold hypertensive devices to a better standard
Read More »NCHR Comments on the USPSTF Draft Recommendation Statement for Human Immunodeficiency Virus (HIV) Infection Screening
We enthusiastically support the efforts of the U.S. Preventive Services Task Force (USPSTF) to re-evaluate its recommendations as new research emerges. We strongly agree with the USPSTF recommendation that clinicians screen adolescents and adults ages 15 to 65, as well pregnant women during their prenatal period or when they present in labor or at delivery and their HIV status is not known.
Read More »